Prostate cancer: Re-focusing on androgen receptor signaling.

TitleProstate cancer: Re-focusing on androgen receptor signaling.
Publication TypeJournal Article
Year of Publication2007
AuthorsNieto M, Finn S, Loda M, Hahn WC
JournalInt J Biochem Cell Biol
Volume39
Issue9
Pagination1562-8
Date Published2007
ISSN1357-2725
KeywordsAnimals, Antineoplastic Agents, Humans, Male, Prostatic Neoplasms, Receptors, Androgen, Signal Transduction
Abstract

Prostate cancer is the most common, non-dermatologic cancer in men. Since prostate cancer is highly associated with increased age, the incidence of this disease is expected to increase as the population ages. In its initial stages prostate cancer depends upon the actions of androgen, and androgen deprivation therapy induces tumor regression. Currently, androgen deprivation is achieved by either surgical or chemical androgen blockade. Unfortunately, nearly all prostate cancer patients develop tumors that grow despite androgen blockade and ultimately relapse. Many alterations in prostate cancer cells contribute to this state. Although chemotherapy induces short remissions in some patients, there are no curative therapies for metastatic disease. This review summarizes our current understanding in androgen signaling and the mechanisms that allow tumor cells to bypass androgen manipulation therapy. The identification of novel survival pathways and effector molecules that drive androgen independent growth is necessary to develop effective therapies for advanced prostate cancers.

DOI10.1016/j.biocel.2007.01.005
Alternate JournalInt J Biochem Cell Biol
PubMed ID17321194
PubMed Central IDPMC2000831
Grant ListK01 CA094223 / CA / NCI NIH HHS / United States
K01 CA094223-05 / CA / NCI NIH HHS / United States
R01 AG023145 / AG / NIA NIH HHS / United States
R01 AG023145-03 / AG / NIA NIH HHS / United States
Related Faculty: 
Massimo Loda, M.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700